Frank Hsu
Direktor/Vorstandsmitglied bei Karin Grunebaum Cancer Research Foundation
Profil
Frank J.
Hsu is a trustee at Karin Grunebaum Cancer Research Foundation.
He was a Senior Director-Medical at Genzyme Corp.
from 2002 to 2012, and Director-Immunology Research Programs at Yale Cancer Center from 1996 to 2002.
He was also a Researcher at Stanford University from 1990 to 1996.
From 2012 to 2013, he served as the Chief Medical Officer at Zyngenia, Inc. He was the Vice President & Head-Oncology at Immune Design Corp.
from 2014 to 2018.
Currently, he is the Chief Medical Officer at Oncternal Therapeutics, Inc. and the Chief Marketing Officer at Apexigen, Inc. Hsu received his undergraduate degree from Stanford University and his doctorate from Harvard Medical School.
Aktive Positionen von Frank Hsu
| Unternehmen | Position | Beginn |
|---|---|---|
| Karin Grunebaum Cancer Research Foundation | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Frank Hsu
| Unternehmen | Position | Ende |
|---|---|---|
| APEXIGEN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.08.2023 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 01.01.2018 |
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2013 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 |
Yale Cancer Center
 Yale Cancer Center Hospital/Nursing ManagementHealth Services Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01.01.2002 |
Ausbildung von Frank Hsu
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ONCTERNAL THERAPEUTICS, INC. | Health Technology |
| APEXIGEN, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT. | Health Services |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
| Karin Grunebaum Cancer Research Foundation |
